2 weeks Ago By ABMN Staff
Evolent Health ( NYSE:EVH – Get Free Report ) is scheduled to be releasing its earnings data after the market closes on Thursday, November 7th. Analysts expect Evolent Health to post earnings of $0.30 per share for the quarter.
Evolent Health has set its Q3 2024 guidance at EPS and its FY 2024 guidance at EPS.Individual interested in listening to the company’s earnings conference call can do so using this link . Evolent Health ( NYSE:EVH – Get Free Report ) last released its earnings results on Thursday, August 8th.
The technology company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.
09. The business had revenue of $647.10 million for the quarter, compared to analyst estimates of $636.
46 million. Evolent Health had a negative net margin of 3.16% and a positive return on equity of 8.
47%. Evolent Health’s revenue for the quarter was up 37.9% on a year-over-year basis.
During the same quarter in the previous year, the business earned $0.06 earnings per share. On average, analysts expect Evolent Health to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Evolent Health Stock Performance Shares of EVH opened at $23.56 on Wednesday. The firm’s fifty day simple moving average is $27.
64 and its two-hundred day simple moving average is $25.03. Evolent Health has a 12 month low of $17.
98 and a 12 month high of $35.00. The company has a current ratio of 1.
08, a quick ratio of 1.08 and a debt-to-equity ratio of 0.57.
The stock has a market capitalization of $2.74 billion, a P/E ratio of -25.06 and a beta of 1.
58. Insider Activity Analyst Ratings Changes Several equities research analysts recently commented on the company. Truist Financial reaffirmed a “buy” rating and set a $33.
00 target price on shares of Evolent Health in a research note on Tuesday, August 27th. JMP Securities reduced their price objective on shares of Evolent Health from $34.00 to $31.
00 and set a “market outperform” rating for the company in a research report on Friday, August 9th. JPMorgan Chase & Co. boosted their target price on shares of Evolent Health from $36.
00 to $45.00 and gave the company an “overweight” rating in a research report on Monday, August 19th. Royal Bank of Canada restated an “outperform” rating and issued a $42.
00 price target on shares of Evolent Health in a report on Tuesday, October 8th. Finally, KeyCorp began coverage on shares of Evolent Health in a report on Friday, October 11th. They set an “overweight” rating and a $35.
00 price objective on the stock. Eleven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $38.
60. Get Our Latest Stock Analysis on EVH Evolent Health Company Profile ( Get Free Report ) Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure.
It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients. Recommended Stories Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter .
.
